Exenatide added to insulin glargine-treated patients with type 2 diabetes provided excellent fasting and postprandial control with weight loss and no increased risk of hypoglycaemia

被引：0
|
作者：
Bergenstal, R. M. [1 ]
Buse, J. B. [2 ]
Glass, L. C. [3 ]
Heilmann, C. R. [3 ]
Lewis, M. S. [3 ]
Kwan, A. Y. M. [4 ]
Hoogwerf, B. J. [4 ]
Rosenstock, J. [5 ]
机构：
[1] Int Diabet Ctr, Minneapolis, MN USA
[2] UNC Sch Med, Chapel Hill, NC USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Lilly USA LLC, Indianapolis, IN USA
[5] Dallas Diabet & Endocrine Ctr, Dallas, TX USA
来源：
DIABETOLOGIA | 2010年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
73
引用
收藏
页码：S37 / S37
页数：1
相关论文
共 50 条
  • [41] Metabolic improvement associated with temporal pattern of weight loss in exenatide-treated patients with type 2 diabetes
    Kendall, D.
    Nielsen, L.
    Han, J.
    Brodows, R.
    Bhole, D.
    [J]. DIABETOLOGIA, 2008, 51 : S353 - S354
  • [42] Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes
    Hanefeld, M.
    Koehler, C.
    Hoffmann, C.
    Wilhelm, K.
    Kamke, W.
    Gerstein, H.
    [J]. DIABETIC MEDICINE, 2010, 27 (02) : 175 - 180
  • [43] Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
    Athena Philis-Tsimikas
    David C. Klonoff
    Kamlesh Khunti
    Harpreet S. Bajaj
    Lawrence A. Leiter
    Melissa V. Hansen
    Lone N. Troelsen
    Steen Ladelund
    Simon Heller
    Thomas R. Pieber
    [J]. Diabetologia, 2020, 63 : 698 - 710
  • [44] Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial
    Philis-Tsimikas, Athena
    Klonoff, David C.
    Khunti, Kamlesh
    Bajaj, Harpreet S.
    Leiter, Lawrence A.
    Hansen, Melissa, V
    Troelsen, Lone N.
    Ladelund, Steen
    Heller, Simon
    Pieber, Thomas R.
    [J]. DIABETOLOGIA, 2020, 63 (04) : 698 - 710
  • [45] REAL-WORLD INCIDENCE OF HYPOGLYCEMIA AND ASSOCIATED COSTS AMONG INSULIN GLARGINE-TREATED PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Xie, L.
    Wei, W.
    Pan, C.
    Baser, O.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A493 - A493
  • [46] Risk of exercise-induced hypoglycaemia in patients with type 2 diabetes on intensive insulin therapy:: Comparison of insulin glargine with NPH insulin as basal insulin supplement
    Ploeckinger, Ursula
    Topuz, Mendaha
    Riese, Brigitte
    Reuter, Thomas
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 81 (03) : 290 - 295
  • [47] Efficacy and Safety of Exenatide QW vs. Placebo Added to Insulin Glargine in Uncontrolled Basal-Insulin Treated Type 2 Diabetes: DURATION-7 Trial
    Frias, Juan P.
    Rosenstock, Julio
    Somogyi, Aniko
    Jabbour, Serge A.
    Wang, Hui
    Hardy, Elise
    Guja, Cristian
    [J]. DIABETES, 2017, 66 : A34 - A35
  • [48] Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naive people with type 2 diabetes initiating basal insulin glargine 100 U/mL
    Landgraf, Wolfgang
    Owens, David R.
    Frier, Brian M.
    Zhang, Mei
    Bolli, Geremia B.
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (03): : 315 - 323
  • [49] Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self-titrating insulin glargine U-100
    Hollander, Priscilla A.
    Kiljanski, Jacek
    Spaepen, Erik
    Harris, Cynthia J.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (11): : 2413 - 2421
  • [50] Confirmed lower risk of hypoglycaemia with insulin glargine versus NPH insulin:: a meta-analysis of 2304 patients with Type 2 diabetes.
    Rosenstock, J
    Benedetti, MM
    Häring, HU
    Lin, Z
    Salzman, A
    [J]. DIABETOLOGIA, 2003, 46 : A304 - A304
12345